 | • レポートコード：MRC2-11QY12060 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、130ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は糸球体腎炎治療のグローバル市場について調査・分析したレポートです。種類別（ACH-5228、AMY-101、アタシセプト、アバコパン、AVX-002）市場規模、用途別（在宅医療、クリニック、病院）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別糸球体腎炎治療の競争状況、市場シェア ・世界の糸球体腎炎治療市場：種類別市場規模 2015年-2020年（ACH-5228、AMY-101、アタシセプト、アバコパン、AVX-002） ・世界の糸球体腎炎治療市場：種類別市場規模予測 2021年-2026年（ACH-5228、AMY-101、アタシセプト、アバコパン、AVX-002） ・世界の糸球体腎炎治療市場：用途別市場規模 2015年-2020年（在宅医療、クリニック、病院） ・世界の糸球体腎炎治療市場：用途別市場規模予測 2021年-2026年（在宅医療、クリニック、病院） ・北米の糸球体腎炎治療市場分析：米国、カナダ ・ヨーロッパの糸球体腎炎治療市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの糸球体腎炎治療市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の糸球体腎炎治療市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの糸球体腎炎治療市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Achillion Pharmaceuticals Inc、Anthera Pharmaceuticals Inc、Biogen Inc、Bristol-Myers Squibb Company、Cellmid Ltd、ChemoCentryx Inc、Complexa Inc、Dimerix Bioscience Pty Ltd、GlaxoSmithKline Plc、Merck KGaA、Omeros Corp、Pfizer Inc、Pharmalink AB、Ra Pharmaceuticals Inc、Retrophin Inc、Rigel Pharmaceuticals Inc、Takeda、Visterra Inc ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Glomerulonephritis Treatment Market
The global Glomerulonephritis Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Glomerulonephritis Treatment Scope and Market Size
Glomerulonephritis Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Glomerulonephritis Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Achillion Pharmaceuticals Inc
Anthera Pharmaceuticals Inc
Biogen Inc
Bristol-Myers Squibb Company
Cellmid Ltd
ChemoCentryx Inc
Complexa Inc
Dimerix Bioscience Pty Ltd
GlaxoSmithKline Plc
Merck KGaA
Omeros Corp
Pfizer Inc
Pharmalink AB
Ra Pharmaceuticals Inc
Retrophin Inc
Rigel Pharmaceuticals Inc
Takeda
Visterra Inc
Market segment by Type, the product can be split into
ACH-5228
AMY-101
Atacicept
Avacopan
AVX-002
Market segment by Application, split into
Home Care
Clinic
Hospital
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Glomerulonephritis Treatment Revenue
1.4 Market by Type
1.4.1 Global Glomerulonephritis Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 ACH-5228
1.4.3 AMY-101
1.4.4 Atacicept
1.4.5 Avacopan
1.4.6 AVX-002
1.5 Market by Application
1.5.1 Global Glomerulonephritis Treatment Market Share by Application: 2020 VS 2026
1.5.2 Home Care
1.5.3 Clinic
1.5.4 Hospital
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Glomerulonephritis Treatment Market Perspective (2015-2026)
2.2 Global Glomerulonephritis Treatment Growth Trends by Regions
2.2.1 Glomerulonephritis Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Glomerulonephritis Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Glomerulonephritis Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Glomerulonephritis Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Glomerulonephritis Treatment Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Glomerulonephritis Treatment Players by Market Size
3.1.1 Global Top Glomerulonephritis Treatment Players by Revenue (2015-2020)
3.1.2 Global Glomerulonephritis Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Glomerulonephritis Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Glomerulonephritis Treatment Market Concentration Ratio
3.2.1 Global Glomerulonephritis Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Glomerulonephritis Treatment Revenue in 2019
3.3 Glomerulonephritis Treatment Key Players Head office and Area Served
3.4 Key Players Glomerulonephritis Treatment Product Solution and Service
3.5 Date of Enter into Glomerulonephritis Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Glomerulonephritis Treatment Historic Market Size by Type (2015-2020)
4.2 Global Glomerulonephritis Treatment Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Glomerulonephritis Treatment Market Size by Application (2015-2020)
5.2 Global Glomerulonephritis Treatment Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Glomerulonephritis Treatment Market Size (2015-2020)
6.2 Glomerulonephritis Treatment Key Players in North America (2019-2020)
6.3 North America Glomerulonephritis Treatment Market Size by Type (2015-2020)
6.4 North America Glomerulonephritis Treatment Market Size by Application (2015-2020)
7 Europe
7.1 Europe Glomerulonephritis Treatment Market Size (2015-2020)
7.2 Glomerulonephritis Treatment Key Players in Europe (2019-2020)
7.3 Europe Glomerulonephritis Treatment Market Size by Type (2015-2020)
7.4 Europe Glomerulonephritis Treatment Market Size by Application (2015-2020)
8 China
8.1 China Glomerulonephritis Treatment Market Size (2015-2020)
8.2 Glomerulonephritis Treatment Key Players in China (2019-2020)
8.3 China Glomerulonephritis Treatment Market Size by Type (2015-2020)
8.4 China Glomerulonephritis Treatment Market Size by Application (2015-2020)
9 Japan
9.1 Japan Glomerulonephritis Treatment Market Size (2015-2020)
9.2 Glomerulonephritis Treatment Key Players in Japan (2019-2020)
9.3 Japan Glomerulonephritis Treatment Market Size by Type (2015-2020)
9.4 Japan Glomerulonephritis Treatment Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Glomerulonephritis Treatment Market Size (2015-2020)
10.2 Glomerulonephritis Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Glomerulonephritis Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Glomerulonephritis Treatment Market Size by Application (2015-2020)
11 India
11.1 India Glomerulonephritis Treatment Market Size (2015-2020)
11.2 Glomerulonephritis Treatment Key Players in India (2019-2020)
11.3 India Glomerulonephritis Treatment Market Size by Type (2015-2020)
11.4 India Glomerulonephritis Treatment Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Glomerulonephritis Treatment Market Size (2015-2020)
12.2 Glomerulonephritis Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Glomerulonephritis Treatment Market Size by Type (2015-2020)
12.4 Central & South America Glomerulonephritis Treatment Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Achillion Pharmaceuticals Inc
13.1.1 Achillion Pharmaceuticals Inc Company Details
13.1.2 Achillion Pharmaceuticals Inc Business Overview
13.1.3 Achillion Pharmaceuticals Inc Glomerulonephritis Treatment Introduction
13.1.4 Achillion Pharmaceuticals Inc Revenue in Glomerulonephritis Treatment Business (2015-2020))
13.1.5 Achillion Pharmaceuticals Inc Recent Development
13.2 Anthera Pharmaceuticals Inc
13.2.1 Anthera Pharmaceuticals Inc Company Details
13.2.2 Anthera Pharmaceuticals Inc Business Overview
13.2.3 Anthera Pharmaceuticals Inc Glomerulonephritis Treatment Introduction
13.2.4 Anthera Pharmaceuticals Inc Revenue in Glomerulonephritis Treatment Business (2015-2020)
13.2.5 Anthera Pharmaceuticals Inc Recent Development
13.3 Biogen Inc
13.3.1 Biogen Inc Company Details
13.3.2 Biogen Inc Business Overview
13.3.3 Biogen Inc Glomerulonephritis Treatment Introduction
13.3.4 Biogen Inc Revenue in Glomerulonephritis Treatment Business (2015-2020)
13.3.5 Biogen Inc Recent Development
13.4 Bristol-Myers Squibb Company
13.4.1 Bristol-Myers Squibb Company Company Details
13.4.2 Bristol-Myers Squibb Company Business Overview
13.4.3 Bristol-Myers Squibb Company Glomerulonephritis Treatment Introduction
13.4.4 Bristol-Myers Squibb Company Revenue in Glomerulonephritis Treatment Business (2015-2020)
13.4.5 Bristol-Myers Squibb Company Recent Development
13.5 Cellmid Ltd
13.5.1 Cellmid Ltd Company Details
13.5.2 Cellmid Ltd Business Overview
13.5.3 Cellmid Ltd Glomerulonephritis Treatment Introduction
13.5.4 Cellmid Ltd Revenue in Glomerulonephritis Treatment Business (2015-2020)
13.5.5 Cellmid Ltd Recent Development
13.6 ChemoCentryx Inc
13.6.1 ChemoCentryx Inc Company Details
13.6.2 ChemoCentryx Inc Business Overview
13.6.3 ChemoCentryx Inc Glomerulonephritis Treatment Introduction
13.6.4 ChemoCentryx Inc Revenue in Glomerulonephritis Treatment Business (2015-2020)
13.6.5 ChemoCentryx Inc Recent Development
13.7 Complexa Inc
13.7.1 Complexa Inc Company Details
13.7.2 Complexa Inc Business Overview
13.7.3 Complexa Inc Glomerulonephritis Treatment Introduction
13.7.4 Complexa Inc Revenue in Glomerulonephritis Treatment Business (2015-2020)
13.7.5 Complexa Inc Recent Development
13.8 Dimerix Bioscience Pty Ltd
13.8.1 Dimerix Bioscience Pty Ltd Company Details
13.8.2 Dimerix Bioscience Pty Ltd Business Overview
13.8.3 Dimerix Bioscience Pty Ltd Glomerulonephritis Treatment Introduction
13.8.4 Dimerix Bioscience Pty Ltd Revenue in Glomerulonephritis Treatment Business (2015-2020)
13.8.5 Dimerix Bioscience Pty Ltd Recent Development
13.9 GlaxoSmithKline Plc
13.9.1 GlaxoSmithKline Plc Company Details
13.9.2 GlaxoSmithKline Plc Business Overview
13.9.3 GlaxoSmithKline Plc Glomerulonephritis Treatment Introduction
13.9.4 GlaxoSmithKline Plc Revenue in Glomerulonephritis Treatment Business (2015-2020)
13.9.5 GlaxoSmithKline Plc Recent Development
13.10 Merck KGaA
13.10.1 Merck KGaA Company Details
13.10.2 Merck KGaA Business Overview
13.10.3 Merck KGaA Glomerulonephritis Treatment Introduction
13.10.4 Merck KGaA Revenue in Glomerulonephritis Treatment Business (2015-2020)
13.10.5 Merck KGaA Recent Development
13.11 Omeros Corp
10.11.1 Omeros Corp Company Details
10.11.2 Omeros Corp Business Overview
10.11.3 Omeros Corp Glomerulonephritis Treatment Introduction
10.11.4 Omeros Corp Revenue in Glomerulonephritis Treatment Business (2015-2020)
10.11.5 Omeros Corp Recent Development
13.12 Pfizer Inc
10.12.1 Pfizer Inc Company Details
10.12.2 Pfizer Inc Business Overview
10.12.3 Pfizer Inc Glomerulonephritis Treatment Introduction
10.12.4 Pfizer Inc Revenue in Glomerulonephritis Treatment Business (2015-2020)
10.12.5 Pfizer Inc Recent Development
13.13 Pharmalink AB
10.13.1 Pharmalink AB Company Details
10.13.2 Pharmalink AB Business Overview
10.13.3 Pharmalink AB Glomerulonephritis Treatment Introduction
10.13.4 Pharmalink AB Revenue in Glomerulonephritis Treatment Business (2015-2020)
10.13.5 Pharmalink AB Recent Development
13.14 Ra Pharmaceuticals Inc
10.14.1 Ra Pharmaceuticals Inc Company Details
10.14.2 Ra Pharmaceuticals Inc Business Overview
10.14.3 Ra Pharmaceuticals Inc Glomerulonephritis Treatment Introduction
10.14.4 Ra Pharmaceuticals Inc Revenue in Glomerulonephritis Treatment Business (2015-2020)
10.14.5 Ra Pharmaceuticals Inc Recent Development
13.15 Retrophin Inc
10.15.1 Retrophin Inc Company Details
10.15.2 Retrophin Inc Business Overview
10.15.3 Retrophin Inc Glomerulonephritis Treatment Introduction
10.15.4 Retrophin Inc Revenue in Glomerulonephritis Treatment Business (2015-2020)
10.15.5 Retrophin Inc Recent Development
13.16 Rigel Pharmaceuticals Inc
10.16.1 Rigel Pharmaceuticals Inc Company Details
10.16.2 Rigel Pharmaceuticals Inc Business Overview
10.16.3 Rigel Pharmaceuticals Inc Glomerulonephritis Treatment Introduction
10.16.4 Rigel Pharmaceuticals Inc Revenue in Glomerulonephritis Treatment Business (2015-2020)
10.16.5 Rigel Pharmaceuticals Inc Recent Development
13.17 Takeda
10.17.1 Takeda Company Details
10.17.2 Takeda Business Overview
10.17.3 Takeda Glomerulonephritis Treatment Introduction
10.17.4 Takeda Revenue in Glomerulonephritis Treatment Business (2015-2020)
10.17.5 Takeda Recent Development
13.18 Visterra Inc
10.18.1 Visterra Inc Company Details
10.18.2 Visterra Inc Business Overview
10.18.3 Visterra Inc Glomerulonephritis Treatment Introduction
10.18.4 Visterra Inc Revenue in Glomerulonephritis Treatment Business (2015-2020)
10.18.5 Visterra Inc Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Glomerulonephritis Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by Glomerulonephritis Treatment Revenue
Table 3. Ranking of Global Top Glomerulonephritis Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Glomerulonephritis Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of ACH-5228
Table 6. Key Players of AMY-101
Table 7. Key Players of Atacicept
Table 8. Key Players of Avacopan
Table 9. Key Players of AVX-002
Table 10. Global Glomerulonephritis Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 11. Global Glomerulonephritis Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 12. Global Glomerulonephritis Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 13. Global Glomerulonephritis Treatment Market Share by Regions (2015-2020)
Table 14. Global Glomerulonephritis Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 15. Global Glomerulonephritis Treatment Market Share by Regions (2021-2026)
Table 16. Market Top Trends
Table 17. Key Drivers: Impact Analysis
Table 18. Key Challenges
Table 19. Glomerulonephritis Treatment Market Growth Strategy
Table 20. Main Points Interviewed from Key Glomerulonephritis Treatment Players
Table 21. Global Glomerulonephritis Treatment Revenue by Players (2015-2020) (Million US$)
Table 22. Global Glomerulonephritis Treatment Market Share by Players (2015-2020)
Table 23. Global Top Glomerulonephritis Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Glomerulonephritis Treatment as of 2019)
Table 24. Global Glomerulonephritis Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 25. Key Players Headquarters and Area Served
Table 26. Key Players Glomerulonephritis Treatment Product Solution and Service
Table 27. Date of Enter into Glomerulonephritis Treatment Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Glomerulonephritis Treatment Market Size by Type (2015-2020) (Million US$)
Table 30. Global Glomerulonephritis Treatment Market Size Share by Type (2015-2020)
Table 31. Global Glomerulonephritis Treatment Revenue Market Share by Type (2021-2026)
Table 32. Global Glomerulonephritis Treatment Market Size Share by Application (2015-2020)
Table 33. Global Glomerulonephritis Treatment Market Size by Application (2015-2020) (Million US$)
Table 34. Global Glomerulonephritis Treatment Market Size Share by Application (2021-2026)
Table 35. North America Key Players Glomerulonephritis Treatment Revenue (2019-2020) (Million US$)
Table 36. North America Key Players Glomerulonephritis Treatment Market Share (2019-2020)
Table 37. North America Glomerulonephritis Treatment Market Size by Type (2015-2020) (Million US$)
Table 38. North America Glomerulonephritis Treatment Market Share by Type (2015-2020)
Table 39. North America Glomerulonephritis Treatment Market Size by Application (2015-2020) (Million US$)
Table 40. North America Glomerulonephritis Treatment Market Share by Application (2015-2020)
Table 41. Europe Key Players Glomerulonephritis Treatment Revenue (2019-2020) (Million US$)
Table 42. Europe Key Players Glomerulonephritis Treatment Market Share (2019-2020)
Table 43. Europe Glomerulonephritis Treatment Market Size by Type (2015-2020) (Million US$)
Table 44. Europe Glomerulonephritis Treatment Market Share by Type (2015-2020)
Table 45. Europe Glomerulonephritis Treatment Market Size by Application (2015-2020) (Million US$)
Table 46. Europe Glomerulonephritis Treatment Market Share by Application (2015-2020)
Table 47. China Key Players Glomerulonephritis Treatment Revenue (2019-2020) (Million US$)
Table 48. China Key Players Glomerulonephritis Treatment Market Share (2019-2020)
Table 49. China Glomerulonephritis Treatment Market Size by Type (2015-2020) (Million US$)
Table 50. China Glomerulonephritis Treatment Market Share by Type (2015-2020)
Table 51. China Glomerulonephritis Treatment Market Size by Application (2015-2020) (Million US$)
Table 52. China Glomerulonephritis Treatment Market Share by Application (2015-2020)
Table 53. Japan Key Players Glomerulonephritis Treatment Revenue (2019-2020) (Million US$)
Table 54. Japan Key Players Glomerulonephritis Treatment Market Share (2019-2020)
Table 55. Japan Glomerulonephritis Treatment Market Size by Type (2015-2020) (Million US$)
Table 56. Japan Glomerulonephritis Treatment Market Share by Type (2015-2020)
Table 57. Japan Glomerulonephritis Treatment Market Size by Application (2015-2020) (Million US$)
Table 58. Japan Glomerulonephritis Treatment Market Share by Application (2015-2020)
Table 59. Southeast Asia Key Players Glomerulonephritis Treatment Revenue (2019-2020) (Million US$)
Table 60. Southeast Asia Key Players Glomerulonephritis Treatment Market Share (2019-2020)
Table 61. Southeast Asia Glomerulonephritis Treatment Market Size by Type (2015-2020) (Million US$)
Table 62. Southeast Asia Glomerulonephritis Treatment Market Share by Type (2015-2020)
Table 63. Southeast Asia Glomerulonephritis Treatment Market Size by Application (2015-2020) (Million US$)
Table 64. Southeast Asia Glomerulonephritis Treatment Market Share by Application (2015-2020)
Table 65. India Key Players Glomerulonephritis Treatment Revenue (2019-2020) (Million US$)
Table 66. India Key Players Glomerulonephritis Treatment Market Share (2019-2020)
Table 67. India Glomerulonephritis Treatment Market Size by Type (2015-2020) (Million US$)
Table 68. India Glomerulonephritis Treatment Market Share by Type (2015-2020)
Table 69. India Glomerulonephritis Treatment Market Size by Application (2015-2020) (Million US$)
Table 70. India Glomerulonephritis Treatment Market Share by Application (2015-2020)
Table 71. Central & South America Key Players Glomerulonephritis Treatment Revenue (2019-2020) (Million US$)
Table 72. Central & South America Key Players Glomerulonephritis Treatment Market Share (2019-2020)
Table 73. Central & South America Glomerulonephritis Treatment Market Size by Type (2015-2020) (Million US$)
Table 74. Central & South America Glomerulonephritis Treatment Market Share by Type (2015-2020)
Table 75. Central & South America Glomerulonephritis Treatment Market Size by Application (2015-2020) (Million US$)
Table 76. Central & South America Glomerulonephritis Treatment Market Share by Application (2015-2020)
Table 77. Achillion Pharmaceuticals Inc Company Details
Table 78. Achillion Pharmaceuticals Inc Business Overview
Table 79. Achillion Pharmaceuticals Inc Product
Table 80. Achillion Pharmaceuticals Inc Revenue in Glomerulonephritis Treatment Business (2015-2020) (Million US$)
Table 81. Achillion Pharmaceuticals Inc Recent Development
Table 82. Anthera Pharmaceuticals Inc Company Details
Table 83. Anthera Pharmaceuticals Inc Business Overview
Table 84. Anthera Pharmaceuticals Inc Product
Table 85. Anthera Pharmaceuticals Inc Revenue in Glomerulonephritis Treatment Business (2015-2020) (Million US$)
Table 86. Anthera Pharmaceuticals Inc Recent Development
Table 87. Biogen Inc Company Details
Table 88. Biogen Inc Business Overview
Table 89. Biogen Inc Product
Table 90. Biogen Inc Revenue in Glomerulonephritis Treatment Business (2015-2020) (Million US$)
Table 91. Biogen Inc Recent Development
Table 92. Bristol-Myers Squibb Company Company Details
Table 93. Bristol-Myers Squibb Company Business Overview
Table 94. Bristol-Myers Squibb Company Product
Table 95. Bristol-Myers Squibb Company Revenue in Glomerulonephritis Treatment Business (2015-2020) (Million US$)
Table 96. Bristol-Myers Squibb Company Recent Development
Table 97. Cellmid Ltd Company Details
Table 98. Cellmid Ltd Business Overview
Table 99. Cellmid Ltd Product
Table 100. Cellmid Ltd Revenue in Glomerulonephritis Treatment Business (2015-2020) (Million US$)
Table 101. Cellmid Ltd Recent Development
Table 102. ChemoCentryx Inc Company Details
Table 103. ChemoCentryx Inc Business Overview
Table 104. ChemoCentryx Inc Product
Table 105. ChemoCentryx Inc Revenue in Glomerulonephritis Treatment Business (2015-2020) (Million US$)
Table 106. ChemoCentryx Inc Recent Development
Table 107. Complexa Inc Company Details
Table 108. Complexa Inc Business Overview
Table 109. Complexa Inc Product
Table 110. Complexa Inc Revenue in Glomerulonephritis Treatment Business (2015-2020) (Million US$)
Table 111. Complexa Inc Recent Development
Table 112. Dimerix Bioscience Pty Ltd Business Overview
Table 113. Dimerix Bioscience Pty Ltd Product
Table 114. Dimerix Bioscience Pty Ltd Company Details
Table 115. Dimerix Bioscience Pty Ltd Revenue in Glomerulonephritis Treatment Business (2015-2020) (Million US$)
Table 116. Dimerix Bioscience Pty Ltd Recent Development
Table 117. GlaxoSmithKline Plc Company Details
Table 118. GlaxoSmithKline Plc Business Overview
Table 119. GlaxoSmithKline Plc Product
Table 120. GlaxoSmithKline Plc Revenue in Glomerulonephritis Treatment Business (2015-2020) (Million US$)
Table 121. GlaxoSmithKline Plc Recent Development
Table 122. Merck KGaA Company Details
Table 123. Merck KGaA Business Overview
Table 124. Merck KGaA Product
Table 125. Merck KGaA Revenue in Glomerulonephritis Treatment Business (2015-2020) (Million US$)
Table 126. Merck KGaA Recent Development
Table 127. Omeros Corp Company Details
Table 128. Omeros Corp Business Overview
Table 129. Omeros Corp Product
Table 130. Omeros Corp Revenue in Glomerulonephritis Treatment Business (2015-2020) (Million US$)
Table 131. Omeros Corp Recent Development
Table 132. Pfizer Inc Company Details
Table 133. Pfizer Inc Business Overview
Table 134. Pfizer Inc Product
Table 135. Pfizer Inc Revenue in Glomerulonephritis Treatment Business (2015-2020) (Million US$)
Table 136. Pfizer Inc Recent Development
Table 137. Pharmalink AB Company Details
Table 138. Pharmalink AB Business Overview
Table 139. Pharmalink AB Product
Table 140. Pharmalink AB Revenue in Glomerulonephritis Treatment Business (2015-2020) (Million US$)
Table 141. Pharmalink AB Recent Development
Table 142. Ra Pharmaceuticals Inc Company Details
Table 143. Ra Pharmaceuticals Inc Business Overview
Table 144. Ra Pharmaceuticals Inc Product
Table 145. Ra Pharmaceuticals Inc Revenue in Glomerulonephritis Treatment Business (2015-2020) (Million US$)
Table 146. Ra Pharmaceuticals Inc Recent Development
Table 147. Retrophin Inc Company Details
Table 148. Retrophin Inc Business Overview
Table 149. Retrophin Inc Product
Table 150. Retrophin Inc Revenue in Glomerulonephritis Treatment Business (2015-2020) (Million US$)
Table 151. Retrophin Inc Recent Development
Table 152. Rigel Pharmaceuticals Inc Company Details
Table 153. Rigel Pharmaceuticals Inc Business Overview
Table 154. Rigel Pharmaceuticals Inc Product
Table 155. Rigel Pharmaceuticals Inc Revenue in Glomerulonephritis Treatment Business (2015-2020) (Million US$)
Table 156. Rigel Pharmaceuticals Inc Recent Development
Table 157. Takeda Company Details
Table 158. Takeda Business Overview
Table 159. Takeda Product
Table 160. Takeda Revenue in Glomerulonephritis Treatment Business (2015-2020) (Million US$)
Table 161. Takeda Recent Development
Table 162. Visterra Inc Company Details
Table 163. Visterra Inc Business Overview
Table 164. Visterra Inc Product
Table 165. Visterra Inc Revenue in Glomerulonephritis Treatment Business (2015-2020) (Million US$)
Table 166. Visterra Inc Recent Development
Table 167. Research Programs/Design for This Report
Table 168. Key Data Information from Secondary Sources
Table 169. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Glomerulonephritis Treatment Market Share by Type: 2020 VS 2026
Figure 2. ACH-5228 Features
Figure 3. AMY-101 Features
Figure 4. Atacicept Features
Figure 5. Avacopan Features
Figure 6. AVX-002 Features
Figure 7. Global Glomerulonephritis Treatment Market Share by Application: 2020 VS 2026
Figure 8. Home Care Case Studies
Figure 9. Clinic Case Studies
Figure 10. Hospital Case Studies
Figure 11. Glomerulonephritis Treatment Report Years Considered
Figure 12. Global Glomerulonephritis Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 13. Global Glomerulonephritis Treatment Market Share by Regions: 2020 VS 2026
Figure 14. Global Glomerulonephritis Treatment Market Share by Regions (2021-2026)
Figure 15. Porter's Five Forces Analysis
Figure 16. Global Glomerulonephritis Treatment Market Share by Players in 2019
Figure 17. Global Top Glomerulonephritis Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Glomerulonephritis Treatment as of 2019
Figure 18. The Top 10 and 5 Players Market Share by Glomerulonephritis Treatment Revenue in 2019
Figure 19. North America Glomerulonephritis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Europe Glomerulonephritis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. China Glomerulonephritis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Japan Glomerulonephritis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Southeast Asia Glomerulonephritis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. India Glomerulonephritis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Central & South America Glomerulonephritis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Bottom-up and Top-down Approaches for This Report
Figure 27. Data Triangulation
Figure 28. Key Executives Interviewed
緩和治療の世界市場（～2026年） Palliative care helps to improve the quality of life of patients and their families facing the problems of serious illness. The main focus of Palliative care is to provide relief from symptoms and stress of a serious illness. Their main goal is to improve the quality of life for both the patient and…- 統合失調感情障害治療の世界市場（～2026年） Types of schizoaffective disorders include manic, depressive, mixed, and schizoaffective disorders. The regional market for schizoaffective affective disorders is very common in North America, Europe and Asia Pacific. Market Analysis and Insights: Global Schizoaffective Disorders Treatment Market Th…
- 糖尿病治療の世界市場（～2026年） Diabetes Treatment is a important way to help manage the healthy ,easy to use and improve the way of the treatment of blood glucose monitoring system. As living standards improve, an increasing obesity, the Diabetes Treatment has improved people's living habits, disease control effect, is becoming m…
- 巨細胞性動脈炎治療の世界市場（～2026年） Giant cell arteritis is also known as temporal arteritis, is a type of disease which causes inflammation of medium and large vessels that occurs only in individuals older than 50 years of age. Seasonal variations in the incidence of giant cell arteritis treatment suggest a possible infective origin …
- 体外血液治療の世界市場（～2026年） The extracorporeal blood treatment is a type of filtration method used to remove many toxins from the blood. The demand for extracorporeal blood treatment is expected to upsurge owing to the growth of kidney diseases. Market Analysis and Insights: Global Extracorporeal Blood Treatment Market The glo…